David Angulo

1.7k total citations · 1 hit paper
33 papers, 1.2k citations indexed

About

David Angulo is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, David Angulo has authored 33 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Infectious Diseases, 25 papers in Epidemiology and 8 papers in Pharmacology. Recurrent topics in David Angulo's work include Antifungal resistance and susceptibility (29 papers), Fungal Infections and Studies (16 papers) and Nail Diseases and Treatments (12 papers). David Angulo is often cited by papers focused on Antifungal resistance and susceptibility (29 papers), Fungal Infections and Studies (16 papers) and Nail Diseases and Treatments (12 papers). David Angulo collaborates with scholars based in United States, Austria and United Kingdom. David Angulo's co-authors include Katyna Borroto–Esoda, Nkechi Azie, Stephen A. Wring, Mahmoud A. Ghannoum, Lisa Long, Christopher Hager, Pranab K. Mukherjee, Jyotsna Chandra, Jack D. Sobel and Laura Kovanda and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and American Journal of Obstetrics and Gynecology.

In The Last Decade

David Angulo

33 papers receiving 1.2k citations

Hit Papers

The Emerging Pathogen Candida auris: Growth Phenotype, Vi... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation
    2017 316 citations Emily L. Larkin, Christopher Hager et al. Antimicrobial Agents and Chemotherapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Angulo United States 18 1.0k 888 143 122 93 33 1.2k
Milena Kordalewska United States 16 1.3k 1.2× 1.0k 1.2× 103 0.7× 46 0.4× 126 1.4× 27 1.4k
Hamed Fakhim Iran 20 784 0.8× 607 0.7× 79 0.6× 54 0.4× 114 1.2× 58 1.0k
Afsane Vaezi Iran 20 841 0.8× 619 0.7× 86 0.6× 41 0.3× 143 1.5× 46 1.1k
Cristina Jiménez‐Ortigosa United States 16 1.4k 1.4× 1.1k 1.3× 170 1.2× 45 0.4× 236 2.5× 23 1.6k
Nicole M. Revie Canada 5 449 0.4× 324 0.4× 83 0.6× 94 0.8× 111 1.2× 8 728
Sevtap Arıkan Türkiye 19 989 1.0× 745 0.8× 134 0.9× 45 0.4× 172 1.8× 40 1.3k
Somanon Bhattacharya United States 10 465 0.4× 346 0.4× 88 0.6× 62 0.5× 106 1.1× 15 738
Leah N. Woosley United States 16 591 0.6× 546 0.6× 243 1.7× 31 0.3× 58 0.6× 23 988
Guanpingsheng Luo United States 13 729 0.7× 526 0.6× 114 0.8× 82 0.7× 48 0.5× 14 853
Abdullah Alqarihi United States 14 623 0.6× 438 0.5× 81 0.6× 54 0.4× 34 0.4× 23 716

Countries citing papers authored by David Angulo

Since Specialization
Citations

This map shows the geographic impact of David Angulo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Angulo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Angulo more than expected).

Fields of papers citing papers by David Angulo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Angulo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Angulo. The network helps show where David Angulo may publish in the future.

Co-authorship network of co-authors of David Angulo

This figure shows the co-authorship network connecting the top 25 collaborators of David Angulo. A scholar is included among the top collaborators of David Angulo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Angulo. David Angulo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Azie, Nkechi, et al.. (2025). A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology. 233(6). 617.e1–617.e18. 1 indexed citations
2.
Sobel, Ryan, Paul Nyirjesy, Steven R. Goldstein, et al.. (2022). Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306. Journal of Women s Health. 32(2). 178–186. 18 indexed citations
3.
Prattes, Juergen, Thomas King, Nkechi Azie, & David Angulo. (2022). P057 All- cause mortality in patients with invasive Candidiasis or candidemia from an interim analysis of a Phase 3 Open-label Study (FURI). Medical Mycology. 60(Supplement_1). 1 indexed citations
4.
Thompson, George R., Thomas King, Nkechi Azie, David Angulo, & Juergen Prattes. (2022). 871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI). Open Forum Infectious Diseases. 9(Supplement_2). 13 indexed citations
5.
Prattes, Juergen, Thomas King, Nkechi Azie, & David Angulo. (2022). P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI). Medical Mycology. 60(Supplement_1). 5 indexed citations
6.
Gamal, Ahmed, Sherman Chu, Thomas S. McCormick, et al.. (2021). Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata. Frontiers in Cellular and Infection Microbiology. 11. 642358–642358. 40 indexed citations
7.
Schwebke, Jane R., Ryan Sobel, Janet Gersten, et al.. (2021). Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clinical Infectious Diseases. 74(11). 1979–1985. 62 indexed citations
8.
Nyirjesy, Paul, et al.. (2021). Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis. Clinical Infectious Diseases. 74(12). 2129–2135. 27 indexed citations
9.
Sobel, Jack D., Katyna Borroto–Esoda, Nkechi Azie, & David Angulo. (2021). In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis. Antimicrobial Agents and Chemotherapy. 65(8). e0056221–e0056221. 17 indexed citations
10.
Azie, Nkechi, et al.. (2020). Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis. Expert Opinion on Investigational Drugs. 29(9). 893–900. 40 indexed citations
11.
Petraitis, Vidmantas, Rūta Petraitienė, Aspasia Katragkou, et al.. (2020). Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy. 64(6). 32 indexed citations
12.
Ghannoum, Mahmoud A., Maiken Cavling Arendrup, Vishnu Chaturvedi, et al.. (2020). Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections. Antibiotics. 9(9). 539–539. 71 indexed citations
13.
Barat, Stephen, et al.. (2019). Ibrexafungerp, a Novel Oral Antifungal, Demonstrates No Reproductive or Developmental Harm in Preclinical Models [25J]. Obstetrics and Gynecology. 133(1). 114S–114S. 2 indexed citations
14.
Nunnally, Natalie S., Kizee A. Etienne, David Angulo, Shawn R. Lockhart, & Elizabeth L. Berkow. (2019). In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations. Antimicrobial Agents and Chemotherapy. 63(11). 47 indexed citations
15.
Barat, Stephen, Katyna Borroto–Esoda, Mahmoud A. Ghannoum, Elizabeth L. Berkow, & David Angulo. (2019). 672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia. Open Forum Infectious Diseases. 6(Supplement_2). S307–S307. 3 indexed citations
16.
Burke, Laurie B., et al.. (2018). The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content.. PubMed. 17(7). 707–714. 8 indexed citations
17.
Larkin, Emily L., Christopher Hager, Jyotsna Chandra, et al.. (2017). The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrobial Agents and Chemotherapy. 61(5). 316 indexed citations breakdown →
18.
Barat, Stephen, Katyna Borroto–Esoda, & David Angulo. (2017). SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration. Open Forum Infectious Diseases. 4(suppl_1). S471–S471. 1 indexed citations
19.
Krishna, Gopal, Malaz Abutarif, Fengjuan Xuan, et al.. (2008). Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(10). 1223–1232. 82 indexed citations
20.
Angulo, David, et al.. (2002). Riesgo anestésico y tipo de herida asociados a infección intrahospitalaria en pacientes quirúrgicos. Modelo logístic. Colombian Journal of Anesthesiology. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Milena Kordalewska Breakdown of academic impact, for papers by Hamed Fakhim Breakdown of academic impact, for papers by Afsane Vaezi Breakdown of academic impact, for papers by Cristina Jiménez‐Ortigosa Breakdown of academic impact, for papers by Nicole M. Revie Breakdown of academic impact, for papers by Sevtap Arıkan Breakdown of academic impact, for papers by Somanon Bhattacharya Breakdown of academic impact, for papers by Leah N. Woosley Breakdown of academic impact, for papers by Guanpingsheng Luo Breakdown of academic impact, for papers by Abdullah Alqarihi
Rankless by CCL
2026